ArticleGynecologic oncology2026
Preoperative hypoalbuminemia and survival among patients selected for primary cytoreduction in advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center Team Ovary study.
Article in Gynecologic oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
objectiveTo examine if preoperative serum albumin (SA) level is associated with worse survival following primary debulking surgery (PDS) for epithelial ovarian cancer (EOC).
methodsIn this retrospective study, we identified patients with stage III-IV EOC who underwent PDS at our institution from 1/1/2015-8/31/2022. Patients were assigned to the low albumin (LA; SA < 3.5 g/dL) or normal albumin (NA; SA ≥ 3.5 g/dL) group. Exclusion criteria included age ≥ 80 years, age 75-79 years with poor physical status or high likelihood of complex surgery, secondary malignancy, and missing preoperative SA level. Median and 5-year progression-free (PFS) and overall survival (OS) rates were calculated using Kaplan-Meier method. Log-rank test was used for categorical variables and Wald test for continuous variables.
resultsOverall, 636 patients were identified, 65 (10%) in the LA and 571 (90%) in the NA group. Median follow-up was 73 months (95% CI: 68-76). Comparing the LA versus NA group, 5-year PFS rate was 18.3% (95% CI: 9.2%-29.9%) vs 26.5% (95% CI: 22.6%-30.5%), respectively (P = 0.107); 5-year OS rate was 56.1% (95% CI: 41.5%-68.4%) vs 66.1% (95% CI: 61.6%-70.3%), respectively (P = 0.053). Complete gross resection (CGR) was achieved in 66% of patients with LA compared to 78% with NA (P = 0.029). On multivariate analysis of OS, age, histology, BRCA status, and CGR were statistically significant prognostic factors, but preoperative SA was not.
conclusionsFive-year survival rates were similar between patients with and without hypoalbuminemia. Relying on preoperative SA level alone, patients may be selected for neoadjuvant chemotherapy who would have equivalent survival outcomes with PDS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.